Update search
Filter
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-9 of 9
Keywords: Docetaxel
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Journal:
Urologia Internationalis
Urol Int (2025) 109 (2): 167–174.
Published Online: 15 October 2024
... prostate cancer (mHSPC). The aim was to assess the efficacy and safety of Darolutamide for mCRPC. Methods: In this single-center, open-label study, patients with previously untreated mCRPC were enrolled and received androgen deprivation therapy (goserelin acetate 3.6 mg every 28 days) and docetaxel (75 mg...
Journal Articles
Journal:
Urologia Internationalis
Urol Int (2022) 106 (8): 784–790.
Published Online: 23 August 2022
... drugs. The aim of our study was to evaluate intravesical gemcitabine + docetaxel (Gem/Doce) versus BCG with respect to quality of life (QOL), safety, and efficacy in NMIBC. Methods: A total of 60 patients with NMIBC were evaluated between July 2019 and December 2020 in a prospective manner. The sample...
Journal Articles
Subject Area:
Further Areas
Journal:
Urologia Internationalis
Urol Int (2021) 105 (5-6): 394–401.
Published Online: 30 March 2021
... in patients with high-risk prostate cancer after primary local therapy (hazard ratio [HR]: 0.87; 95% confidence interval [CI], 0.72–1.05; p = 0.15). But docetaxel in patients with high-risk prostate cancer after primary local therapy was associated with a slightly OS improvement (HR: 0.79; 95% CI, 0.63–0.98...
Journal Articles
Subject Area:
Further Areas
Holger Hans Herman Erb, Peter Sparwasser, Tamara Diehl, Manuela Hemmerlein-Thomas, Igor Tsaur, Eva Jüngel, Ulrich Sommer, Gustavo B. Baretton, Axel Haferkamp, Andreas Neisius, Christian Thomas
Journal:
Urologia Internationalis
Urol Int (2020) 104 (3-4): 253–262.
Published Online: 17 January 2020
... = 26) before, while, and after undergoing a new therapy with chemotherapy (cabazitaxel or docetaxel) or antiandrogen (enzalutamide or abiraterone). CTCs were sequentially cytospun on object slides, and AR-V7 status was then detected by IHC based on a staining regime established on a 22Rv1 cell line...
Journal Articles
Subject Area:
Further Areas
Christopher Darr, Ulrich Krafft, Boris Hadaschik, Stephan Tschirdewahn, Sabina Sevcenco, Anita Csizmarik, Peter Nyirady, Zsófia Küronya, Henning Reis, Agnieszka Maj-Hes, Shahrokh F. Shariat, Gero Kramer, Tibor Szarvas
Journal:
Urologia Internationalis
Urol Int (2018) 101 (1): 65–73.
Published Online: 27 June 2018
... resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer patients who underwent DOC-therapy...
Journal Articles
Subject Area:
Further Areas
Journal:
Urologia Internationalis
Urol Int (2015) 95 (1): 114–119.
Published Online: 14 May 2015
...Shulu Zu; Weiming Ma; Pan Xiao; Yazhou Cui; Tianjia Ma; Chunwen Zhou; Huaiqiang Zhang Objectives: Docetaxel was the first drug with proven survival benefit in men with castration-resistant prostate cancer. Acquired resistance to docetaxel precedes fatality in castration-resistant prostate cancer...
Journal Articles
Subject Area:
Further Areas
Journal:
Urologia Internationalis
Urol Int (2013) 90 (1): 56–61.
Published Online: 08 November 2012
...Ali Shamseddine; Fadi S. Farhat; Elias Elias; Raja B. Khauli; Ahmad Saleh; Mohammad A. Bulbul Introduction: Docetaxel has become the standard chemotherapy for patients with castration-resistant prostate cancer (CRPC). We wanted to assess the efficacy and safety of a weekly high-dose calcitriol...
Journal Articles
Subject Area:
Further Areas
Natsuki Takaha, Koji Okihara, Kazumi Kamoi, Fumiya Hongo, Tsuyoshi Iwata, Kimihiro Yano, Takashi Ueda, Ichiro Takeuchi, Takeshi Yamada, Akihiro Kawauchi, Tsuneharu Miki
Journal:
Urologia Internationalis
Urol Int (2011) 87 (3): 263–269.
Published Online: 26 August 2011
...Natsuki Takaha; Koji Okihara; Kazumi Kamoi; Fumiya Hongo; Tsuyoshi Iwata; Kimihiro Yano; Takashi Ueda; Ichiro Takeuchi; Takeshi Yamada; Akihiro Kawauchi; Tsuneharu Miki Objectives: To evaluate the efficacy and safety of docetaxel-based chemotherapy for elderly metastatic castration-resistant...
Journal Articles
Subject Area:
Further Areas
Andreas P. Berger, Mathias Niescher, Reiner Fischer-Colbrie, Alexandre Pelzer, Georg Bartsch, Wolfgang Horninger
Journal:
Urologia Internationalis
Urol Int (2004) 73 (2): 110–112.
Published Online: 27 August 2004
... not been demonstrated yet. Docetaxel alone or in combination with estramustine has been shown to exhibit a high level of activity in the treatment of hormone-refractory prostate cancer. To date there are only few reports on chemotherapy for localized prostate cancer. Methods: The efficacy and safety...
